SirPAD Study Results to be Presented at VIVA 2026
New results from the SirPAD randomized trial, focusing on patients with femoropopliteal peripheral artery disease causing claudication, will be presented at VIVA 2026 in Las Vegas.
New findings from the SirPAD randomized trial are scheduled for presentation at the VIVA 2026 conference, taking place October 3–6 in Las Vegas. The study specifically addresses femoropopliteal peripheral artery disease (PAD) in patients experiencing intermittent claudication.
The SirPAD trial enrolled a total of 1,252 patients and aims to compare different treatment modalities for this condition. Femoropopliteal PAD involves blockages in the arteries of the thigh and behind the knee, restricting blood flow to the lower extremities and causing pain during physical activity.
VIVA 2026 is an event for vascular surgery and endovascular treatment specialists. The presentation of the SirPAD results is expected to provide significant clinical data for healthcare professionals.
Research into PAD is crucial for improving patient quality of life and preventing severe outcomes. The data shared from the SirPAD study is anticipated to inform current treatment guidelines and practices for managing claudication.